SOURCE: Milestone Scientific, Inc.

Milestone Scientific

May 28, 2015 07:30 ET

Milestone Scientific Announces Approval for Listing on the NYSE MKT

LIVINGSTON, NJ--(Marketwired - May 28, 2015) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that its shares of common stock have been approved for listing on the NYSE MKT, subject to continued satisfaction of listing requirements. Trading on the NYSE MKT is expected to commence on June 1, 2015. The Company will continue to trade under the symbol "MLSS."

"Trading on the NYSE MKT is an important development for the Company and reflects our continued progress as we move forward with our medical instruments. These instruments represent a leap forward in drug delivery technology, which remained relatively unchanged since the invention of the hypodermic syringe in the 1800s. Our computer-controlled instruments are designed to provide safe, controlled and painless injections, as well as help reduce costs and malpractice risk for healthcare professionals," commented Leonard Osser, CEO of Milestone Scientific. "Listing on the NYSE MKT should provide the Company increased exposure within the investment community and improved liquidity."

NYSE MKT is a fully integrated trading venue within the NYSE community and leverages the NYSE's advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE community.

"We welcome Milestone Scientific to the NYSE MKT family of listed companies," said Garvis Toler, Global Head of Capital Markets, NYSE. "Milestone will be joining other well-known medical device companies taking advantage of the NYSE's advanced and innovative market model to offer a premier value for listing and trading their stocks."

About Milestone Scientific

Milestone Scientific Inc. (MLSS) is a medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website:

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact Information

  • Contact:
    David Waldman or Klea Theoharis
    Crescendo Communications, LLC
    Tel: 212-671-1020